Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SWTX 
SpringWorks Therapeutics Inc (SWTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: SWTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $47
1 Year Target Price $47
| 0 | Strong Buy |
| 0 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.4% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.54B USD | Price to earnings Ratio - | 1Y Target Price 47 |
Price to earnings Ratio - | 1Y Target Price 47 | ||
Volume (30-day avg) 6 | Beta 0.7 | 52 Weeks Range 28.21 - 62.00 | Updated Date 06/30/2025 |
52 Weeks Range 28.21 - 62.00 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.41 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -115.6% | Operating Margin (TTM) -164.07% |
Management Effectiveness
Return on Assets (TTM) -28.47% | Return on Equity (TTM) -51.57% |
Valuation
Trailing PE - | Forward PE 322.58 | Enterprise Value 3260169275 | Price to Sales(TTM) 16.12 |
Enterprise Value 3260169275 | Price to Sales(TTM) 16.12 | ||
Enterprise Value to Revenue 14.84 | Enterprise Value to EBITDA -7.9 | Shares Outstanding 75349000 | Shares Floating 74164233 |
Shares Outstanding 75349000 | Shares Floating 74164233 | ||
Percent Insiders 1.28 | Percent Institutions 87.36 |
Analyst Ratings
Rating 3 | Target Price 47 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 6 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
SpringWorks Therapeutics Inc
Company Overview
History and Background
SpringWorks Therapeutics was founded in 2017 and is focused on developing and commercializing life-changing medicines for patients with severe rare diseases and cancer.
Core Business Areas
- Oncology: Focuses on developing therapies for rare cancers, targeting specific genetic mutations or pathways.
- Rare Diseases: Develops treatments for rare diseases with significant unmet medical needs.
Leadership and Structure
Saqib Islam is the Chief Executive Officer. The company has a board of directors and operates with distinct functional departments covering research, development, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Ogsiveo (nirogacestat): A gamma secretase inhibitor approved for desmoid tumors. Market share data is still emerging. Competitors include standard of care like surgery, radiation, or watch and wait, and other kinase inhibitors and chemotherapeutic regimens. The revenue is expected to increase substantially based on the recent approval.
Market Dynamics
Industry Overview
The biopharmaceutical industry, specifically rare disease and oncology segments, is characterized by high R&D costs, long development timelines, and regulatory scrutiny. Increasing demand for personalized medicine and orphan drugs is driving growth.
Positioning
SpringWorks Therapeutics is positioned as a leader in developing therapies for rare cancers and diseases with high unmet needs. Its competitive advantage lies in its targeted therapies and focus on underserved patient populations.
Total Addressable Market (TAM)
The TAM for rare diseases and oncology is estimated to be billions of dollars. SpringWorks is focused on a portion of this TAM based on the diseases it is targeting. Their positioning in the desmoid tumor market and potentially other rare tumor markets allows them to capture a significant portion of their applicable TAM.
Upturn SWOT Analysis
Strengths
- Approved product (Ogsiveo)
- Strong pipeline of product candidates
- Experienced management team
- Focus on rare diseases and oncology
Weaknesses
- Reliance on a limited number of products
- High R&D expenses
- Dependence on regulatory approvals
- Competition from established pharmaceutical companies
Opportunities
- Expansion of Ogsiveo label to other indications
- Acquisition or in-licensing of new product candidates
- Partnerships with other pharmaceutical companies
- Geographic expansion
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from biosimilars or generics
- Changes in healthcare regulations
Competitors and Market Share
Key Competitors
- BMY
- MRK
- LLY
- GILD
Competitive Landscape
SpringWorks's focus on rare diseases and specific oncology targets provides a niche advantage. However, they face competition from larger, more established pharmaceutical companies with broader portfolios and greater resources.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by pipeline progress and, more recently, initial sales of Ogsiveo.
Future Projections: Future growth is dependent on the continued commercial success of Ogsiveo and the development and approval of other product candidates.
Recent Initiatives: Recent initiatives include the FDA approval of Ogsiveo and the advancement of other clinical programs.
Summary
SpringWorks Therapeutics is a promising company focused on rare diseases and oncology. The recent approval of Ogsiveo is a significant milestone. The company's future success hinges on its ability to successfully commercialize Ogsiveo and advance its pipeline of product candidates, while managing the risks associated with regulatory approvals and competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SpringWorks Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary depending on the source. Financial data should be verified from official company filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About SpringWorks Therapeutics Inc
Exchange NASDAQ | Headquaters Stamford, CT, United States | ||
IPO Launch date 1987-06-05 | CEO & Director Mr. Saqib Islam J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 368 | Website https://www.springworkstx.com |
Full time employees 368 | Website https://www.springworkstx.com | ||
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor of MEK1 and MEK2 for the treatment of adult and pediatric patients two years of age and older with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The company also develops Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer; and mirdametinib for the treatment of solid tumors harboring other MAPK aberrations, including for the treatment of pediatric and young adult patients with low-grade gliomas that is in Phase 1/2 clinical trial. In addition, its products under development include Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has license agreements with Pfizer Inc. for nirogacestat and mirdametinib; and Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.